Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans.
In this randomized, double-blind placebo controlled trial our objectives were to determine if acetazolamide is capable of preventing high altitude pulmonary edema (HAPE) in trekkers traveling between 4250 m (Pheriche)\4350 m (Dingboche) and 5000 m (Lobuje) in Nepal; to determine if acetazolamide dec...
Main Authors: | Basnyat, B, Hargrove, J, Holck, P, Srivastav, S, Alekh, K, Ghimire, L, Pandey, K, Griffiths, A, Shankar, R, Kaul, K, Paudyal, A, Stasiuk, D, Basnyat, R, Davis, C, Southard, A, Robinson, C, Shandley, T, Johnson, D, Zafren, K, Williams, S, Weiss, E, Farrar, J, Swenson, E |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
Findings of cognitive impairment at high altitude: relationships to acetazolamide use and acute mountain sickness
by: Phillips, L, et al.
Published: (2017) -
Steady‐state chemoreflex drive captures ventilatory acclimatization during incremental ascent to high altitude: Effect of acetazolamide
by: Valerie C. Cates, et al.
Published: (2022-12-01) -
Effect of sildenafil and acclimatization on cerebral oxygenation at altitude.
by: Chan, C, et al.
Published: (2005) -
Letter to the Editor: COVID-19 lung injury Is different from high altitude pulmonary edema
by: Brugger, H, et al.
Published: (2020) -
The light is gone: Tribute to Prakash Adhikari, Executive Director of the Himalayan Rescue Association
by: Basnyat, B, et al.
Published: (2021)